Key Developments: Harvard Bioscience Inc (HBIO.OQ)

HBIO.OQ on NASDAQ Stock Exchange Global Market

5.22USD
4:00pm EDT
Price Change (% chg)

$-0.13 (-2.43%)
Prev Close
$5.35
Open
$5.30
Day's High
$5.30
Day's Low
$5.16
Volume
53,347
Avg. Vol
39,432
52-wk High
$6.15
52-wk Low
$3.60

Search Stocks

Latest Key Developments (Source: Significant Developments)

Harvard Bioscience Inc Announces Retirement Of CEO And Appointment Of Interim CEO
Wednesday, 15 May 2013 07:30am EDT 

Harvard Bioscience Inc announced that its Board of Directors has appointed David Green, the Company's President and as interim Chief Executive Officer (CEO) following the retirement and resignation of Chane Graziano as CEO and a Director of the Company. The Board of Directors will immediately commence a search to hire a new CEO .  Full Article

Harvard Bioscience Inc Announces Postponement Of IPO For Harvard Apparatus Regenerative Technology Inc
Tuesday, 9 Apr 2013 05:22pm EDT 

Harvard Bioscience Inc announced that the planned Initial Public Offering (IPO) by its wholly-owned regenerative medicine device subsidiary, Harvard Apparatus Regenerative Technology, Inc., or HART, has been postponed due to market conditions. Harvard Bioscience continues to believe that the best path to maximizing value for its shareholders is to separate its regenerative medicine device business from its profitable core life science research tools business.  Full Article

Harvard Bioscience Inc Revises FY 2012 Guidance; Issues Q4 2012 Guidance
Thursday, 1 Nov 2012 07:01am EDT 

Harvard Bioscience Inc announced that based on the current trends, for core Life Science Research Tools business it expects revenues for fiscal 2012 to be in the $111-$113 million range and non-GAAP adjusted diluted earnings per share (EPS) to be in the $0.39-$0.40 range. This is the low end of original earnings guidance for the year. For the fourth quarter, in Life Science Research Tools business it expects revenues to be in the $28-$30 million range and non-GAAP adjusted diluted earnings per share to be in the 11-12 cents range.  Full Article

Harvard Bioscience Reaffirms FY 2012 Guidance; Issues Q3 2012 Guidance
Thursday, 2 Aug 2012 07:00am EDT 

Harvard Bioscience announced that it maintaining its fiscal 2012 guidance for its core LSRT business at $115-120 million for revenues and $0.39-40.42 for non-GAAP adjusted diluted earnings per share. The Company also expects revenues for its core LSRT business in the third quarter to be in the $27-28 million range and non-GAAP adjusted diluted earnings per share to be in the $0.09-$0.10 range.  Full Article

Harvard Bioscience Issues Q2 2012 Guidance; Reaffirms FY 2012 Guidance
Thursday, 3 May 2012 07:01am EDT 

Harvard Bioscience announced that for second quarter of 2012, it expects revenues to be in the $28-$29 million range and non-GAAP diluted earnings per share for our core LSRT business to be in the 9-10 cents per share range. For fiscal 2012, it expects $115-$120 million range for revenues and 39-42 cents non-GAAP diluted earnings per share range for our core LSRT business.  Full Article

Harvard Bioscience Issues FY, Q1 2012 Guidance
Thursday, 1 Mar 2012 07:00am EST 

Harvard Bioscience announced that for fiscal 2012, it expect revenues to be $115-$120 million, and diluted non-GAAP adjusted earnings per share for core LSRT business to be in the $0.39 - $0.42 range. In the first quarter of 2012, it expect revenues to be in the $27-$28 million range, and for LSRT diluted non-GAAP adjusted earnings per share to be in the $0.08 - $0.09 range.  Full Article

Harvard Bioscience Acquires AHN
Tuesday, 7 Feb 2012 06:15pm EST 

Harvard Bioscience announced that it has acquired the business of AHN Biotechnologie GmbH through its wholly owned Biochrom Ltd. subsidiary. AHN is a privately held manufacturer of plastic consumable laboratory products including pipette tips. This acquisition is complementary to the current Biochrom product line of molecular biology instruments. Terms were not disclosed.  Full Article

Harvard Bioscience Issues Q4 2011 Guidance; Lowers FY 2011 Guidance
Thursday, 3 Nov 2011 06:45am EDT 

Harvard Bioscience announced that for fourth quarter of 2011, it expects revenue to be in the range of $27.5-28.5 million range and non-GAAP adjusted diluted earnings per share (EPS) for the core Life Science Research Tools business to be in the 9-10 cents range. For fiscal 2011, it expects revenues to be in the $107.5-$108.5 million range and non-GAAP adjusted diluted earnings per share for the core Life Science Research Tools business to be in the $0.34-$0.35 range.  Full Article

Search Stocks